From artificial red blood cells, oxygen carriers, and oxygen therapeutics to artificial cells, nanomedicine, and beyond

Chang, Thomas Ming Swi

doi:10.3109/10731199.2012.662408

Cited by 56 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29,40 The Hb used in these systems is usually derived from outdated human or bovine RBCs or from recombinant technologies. [40][41][42][43][44][45][46] When using outdated human or bovine RBCs, the Hb is isolated via cell lysis, purified by sterile filtration and chromatographic techniques and sterilized (e.g., by low heat). 47 The oxygen-binding equilibrium kinetics of Hb is positively cooperative in nature, where the Hb binds the first O 2 slowly, which in turn increases the binding affinity for the second, third, and fourth O 2 molecule to Hb, resulting in the classic sigmoidal O 2 equilibrium curve (OEC).…”

Section: Hboc Systemsmentioning

confidence: 99%

Bio‐inspired nanomedicine strategies for artificial blood components

Gupta

2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Blood is a fluid connective tissue where living cells are suspended in non-cellular liquid matrix. The cellular components of blood render gas exchange (RBCs), immune surveillance (WBCs) and hemostatic responses (platelets), and the non-cellular components (salts, proteins etc.) provide nutrition to various tissues in the body. Dysfunction and deficiencies in these blood components can lead to significant tissue morbidity and mortality. Consequently, transfusion of whole blood or its components is a clinical mainstay in the management of trauma, surgery, myelosuppression and congenital blood disorders. However, donor-derived blood products suffer from issues of shortage in supply, need for type matching, high risks of pathogenic contamination, limited portability and shelf-life, and a variety of side-effects. While robust research is being directed to resolve these issues, a parallel clinical interest has developed towards bioengineering of synthetic blood substitutes that can provide blood’s functions while circumventing the above problems. Nanotechnology has provided exciting approaches to achieve this, using materials engineering strategies to create synthetic and semi-synthetic RBC substitutes for enabling oxygen transport, platelet substitutes for enabling hemostasis and WBC substitutes for enabling cell-specific immune response. Some of these approaches have further extended the application of blood cell-inspired synthetic and semi-synthetic constructs for targeted drug delivery and nanomedicine. The current article will provide a comprehensive review of the various nanotechnology approaches to design synthetic blood cells, along with a critical discussion of successes and challenges of the current state-of-art in this field.

show abstract

Section: Hboc Systemsmentioning

confidence: 99%

Bio‐inspired nanomedicine strategies for artificial blood components

Gupta

2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…In part, resistance to adhesion is mediated by the RBC glycocalyx, which contains abundant negatively charged sialic acids [57]. As might be predicted by these findings, it has proven to be extraordinarily difficult to replicate RBC flexibility and resistance to adherence using artificial blood substitutes, which likely has contributed to their limited clinical success notwithstanding decades of investigation [58,59]. …”

Section: Rbc Features As Drug Carriersmentioning

confidence: 99%

Delivery of Drugs Bound to erythrocytes: New Avenues for an Old Intravascular Carrier

et al. 2015

View full text Add to dashboard Cite

For several decades, researchers have used erythrocytes for drug delivery of a wide variety of therapeutics in order to improve their pharmacokinetics, biodistribution, controlled release and pharmacodynamics. Approaches include encapsulation of drugs within erythrocytes, as well as coupling of drugs onto the red cell surface. This review focuses on the latter approach, and examines the delivery of red blood cell (RBC)-surface-bound anti-inflammatory, anti-thrombotic and anti-microbial agents, as well as RBC carriage of nanoparticles. Herein, we discuss the progress that has been made in surface loading approaches, and address in depth the issues relevant to surface loading of RBC, including intrinsic features of erythrocyte membranes, immune considerations, potential surface targets and techniques for the production of affinity ligands.

show abstract

“…PEG can also stabilize the particles in the aqueous medium of blood and prolong the systemic circulation of the micelles (Li et al, 2011). The use of PEG in this type of micelle is described in the literature (Shi et al, 2009), as is its use in HBOC lipid vesicles to improve the circulation time (Cabrales et al, 2012;Centis and Vermette, 2008;Chang, 2012).…”

Section: Dendrimers and Micelles Oxygen Carriersmentioning

confidence: 99%

Tissue engineering red blood cells: a therapeutic

Veen

Hunt

2014

J Tissue Eng Regen Med

View full text Add to dashboard Cite

The use of red blood cells (RBCs) in transfusion is widespread in modern medicine. Limitations in blood transfusion have made an urgent argument for the focus on alternatives, as particular medical treatments heavily rely on the supply of donated blood. Stem cells have been successfully used in vitro to produce RBCs and researchers are currently challenged with developing larger-scale culture methods to meet the requirements for clinically relevant cell numbers. The ultimate conditions that will be beneficial for this type of research are trivial. A successful human clinical trial has shown that tremendous progress has already been made in this field. Other alternatives are based on the oxygen carrier protein that RBCs contain, i.e. haemoglobin (Hb). Chemically defined molecules and crosslinked proteins, which are able to bind and transport oxygen, have been found to be functional in vivo. Major progress has been achieved, but developing highly suitable products for the transfusion market still remains an enormous challenge for these acellular blood substitutes. We provide a review about developing alternatives for blood transfusion, with the emphasis on tissue-engineering approaches.

show abstract

From artificial red blood cells, oxygen carriers, and oxygen therapeutics to artificial cells, nanomedicine, and beyond

Cited by 56 publications

References 17 publications

Bio‐inspired nanomedicine strategies for artificial blood components

Bio‐inspired nanomedicine strategies for artificial blood components

Delivery of Drugs Bound to erythrocytes: New Avenues for an Old Intravascular Carrier

Tissue engineering red blood cells: a therapeutic

Contact Info

Product

Resources

About